Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA). The company sells the Inspire system, which is the first and only FDA-approved neurostimulation technology for treating moderate to severe OSA. Inspire Medical Systems markets its products primarily to hospitals and ambulatory surgery centers across the U.S., Europe, Japan, Singapore, and Hong Kong.
- Inspire System - Provides a neurostimulation technology that delivers mild hypoglossal nerve stimulation to maintain an open airway during sleep, specifically designed for patients with moderate to severe OSA who cannot tolerate or fail positive airway pressure treatments.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Timothy P. Herbert ExecutiveBoard | President, CEO, and Chair of the Board | None | Founder of INSP, instrumental in developing proprietary neurostimulation technology, led IPO and significant growth. | View Report → |
Bryan K. Phillips Executive | SVP, General Counsel, Chief Compliance Officer, and Corporate Secretary | None | Joined INSP in 2021, previously Chief Legal Officer at Cerevel Therapeutics, extensive legal and compliance experience. | |
Carlton W. Weatherby Executive | Chief Strategy and Growth Officer | None | Joined INSP in 2023, previously VP and GM at Medtronic, extensive MedTech industry experience. | |
Charisse Y. Sparks, M.D. Executive | Chief Medical Officer | Board Advisor at NuShores Biosciences, Digital Health Portugal; Board Member at Sparkle Peach, Inc.; Steering Committee Chair at AvaMed, MedTech Color Collaborative Community | Joined INSP in 2023, previously CMO at AppliedVR, Inc., and VP at DePuy Synthes. | |
John C. Rondoni Executive | Chief Technology Officer | None | Joined INSP in 2008, over 20 years in medical device development, previously at Medtronic. | |
Randall A. Ban Executive | Chief Commercial Officer | None | Joined INSP in 2009, led sales and marketing efforts, previously at Boston Scientific and Guidant Corporation. | |
Richard J. Buchholz Executive | Chief Financial Officer | None | Joined INSP in 2014, previously CFO at superDimension, Ltd., extensive financial management experience. | |
Steven L. Jandrich Executive | Vice President, Human Resources | None | Joined INSP in 2017, previously VP of HR at Link Snacks, Inc., and St. Jude Medical. | |
Casey M. Tansey Board | Director | Managing Partner at U.S. Venture Partners | Over three decades in the medical device industry, previously CEO of Heartport. | |
Cynthia B. Burks Board | Director | Board Member at WD-40 Company, Torch, Sellars Absorbent Materials Company, Juma Ventures | Extensive expertise in human capital strategy, previously SVP and Chief People and Culture Officer at Genentech. | |
Dana G. Mead, Jr. Board | Director | Director at Inari Medical Inc., Pulmonx Corporation | Extensive healthcare and medical device industry experience, previously CEO of HeartFlow, Inc.. | |
Gary L. Ellis Board | Lead Independent Director | Board Member at The Toro Company | Extensive financial expertise, previously EVP and CFO at Medtronic, joined INSP Board in 2019. | |
Georgia Garinois-Melenikiotou Board | Director | Director at Pulmonx Corporation, Natura & Co, Douglas Group (nominee) | Extensive experience in global consumer marketing, previously EVP at The Estée Lauder Companies. | |
Shawn T. McCormick Board | Director | Board Member at Nevro Corp. | Extensive financial expertise, previously CFO at Aldevron, LLC, and Tornier N.V.. | |
Shelley G. Broader Board | Director | Board Member at Dutch Bros Inc., Loblaw Companies Limited, IFCO Systems, Moffitt Cancer Center | Extensive C-suite leadership experience, previously CEO of Chico’s FAS, Inc., and executive roles at Walmart. |
- "Can you provide more clarity on the potential impact of the DOJ civil investigative demand on your operations, and what steps are you taking to mitigate any risks associated with this investigation? "
- "Given that international revenue remains a small percentage of total revenue and is not expected to significantly increase in 2025, what are the challenges you face in accelerating growth outside the U.S., and how do you plan to address them? "
- "With the upcoming full launch of the Inspire V system, how are you managing the risk of patients delaying procedures to wait for the new device, and what impact do you expect this to have on your near-term revenues? "
- "Your guidance assumes continued sequential growth in revenue throughout the year; however, considering potential competition entering the market, how confident are you in achieving your revenue targets, and what contingencies do you have in place? "
- "You mentioned plans to improve profitability in 2025 despite ongoing investments; can you elaborate on the specific cost-saving measures or operational efficiencies you intend to implement to achieve this? "
Research analysts who have asked questions during Inspire Medical Systems earnings calls.
Adam Maeder
Piper Sandler Companies
4 questions for INSP
Anthony Petrone
Mizuho Group
4 questions for INSP
Brett Fishbin
KeyBanc Capital Markets
4 questions for INSP
Danielle Antalffy
UBS Group AG
4 questions for INSP
David Rescott
Baird
4 questions for INSP
Jonathan Block
Stifel Financial Corp.
4 questions for INSP
Richard Newitter
Truist Securities
4 questions for INSP
Robert Marcus
JPMorgan Chase & Co.
4 questions for INSP
Travis Steed
Bank of America
4 questions for INSP
Christopher Pasquale
Nephron Research
3 questions for INSP
Larry Biegelsen
Wells Fargo & Company
3 questions for INSP
Michael Polark
Wolfe Research
3 questions for INSP
Michael Sarcone
Jefferies
3 questions for INSP
Shagun Singh Chadha
RBC Capital Markets
3 questions for INSP
Michael Kratky
Leerink Partners
2 questions for INSP
Suraj Kalia
Oppenheimer & Co. Inc.
2 questions for INSP
Brett Netson
Leerink Partners
1 question for INSP
Chris Pasquale
Nephron Research LLC
1 question for INSP
Kallum Titchmarsh
Morgan Stanley
1 question for INSP
Lawrence Biegelsen
Wells Fargo
1 question for INSP
Mike Kratky
Leerink Partners
1 question for INSP
Mike Polark
Wolfe Research, LLC
1 question for INSP
Shagun Singh
RBC Capital Markets
1 question for INSP
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
EnsoData, Inc. | 2022 | In 2022, Inspire Medical Systems made a $10 million minority investment in EnsoData to support its digital health platform and improve patient experience by addressing bottlenecks in sleep study analysis. The acquisition leverages EnsoData’s AI-powered, FDA-approved EnsoSleep platform, which operates in over 500 sleep centers and analyzes more than 30,000 sleep studies per month. |
Recent press releases and 8-K filings for INSP.
- Inspire Medical Systems is making significant progress on the transition to Inspire five, with 99% of surgeons certified, over 80% of contracts executed, and over 60%, closer to 65%, of sleep sync programmers implemented, expecting full adoption by the end of FY 2025.
- The company attributes its guidance reduction to temporary headwinds, including patient warehousing for Inspire five and destocking of Inspire four inventory, which are expected to abate by year-end, with some catch-up spilling into 2026.
- Inspire Medical acknowledges the impact of GLP-1s, noting both patients entering their funnel due to BMI reduction and others delaying treatment, but it is still too early to quantify the long-term net effect.
- The company is confident in its competitive position against the new Nexvaxia device, citing Inspire's significantly lower trial dropout rate (2% vs. 25%), lower adverse event rate (2% vs. closer to 10%), and shorter procedural time (45-60 minutes vs. 132 minutes).
- For FY 2026, Inspire expects growth acceleration, driven by full Inspire five adoption, footprint expansion, and proposed increases in physician reimbursement rates for Inspire five (from $600 to $660).
- Inspire Medical Systems' Chief Financial Officer, Richard J. Buchholz, will step down by the end of 2025 but will serve in an advisory role through February 2026 for a smooth transition.
- His departure is for other professional opportunities and is not due to any disputes or disagreements with the company.
- The company has initiated a search for a new CFO with an executive search firm.
- Inspire Medical Systems reaffirmed its full-year 2025 financial guidance, projecting revenues between $900 million to $910 million and earnings per share between 40 to 50 cents.
- The Portnoy Law Firm has initiated an investigation into possible securities fraud at Inspire Medical Systems, Inc..
- This follows Inspire's August 4, 2025, announcement of revised full-year 2025 guidance, lowering revenue to a range of $900 million to $910 million and diluted net income per share to $0.40 to $0.50.
- The company attributed the revised outlook to slower-than-expected progress in the commercial launch of its next-generation Inspire V neurostimulation system.
- Following the announcement, Inspire's stock price declined $42.04 per share, or approximately 32.35%, closing at $87.91 per share on August 5, 2025.
- In May 2025, Inspire Medical Systems introduced both the Inspire five and Inspire V systems, featuring an internal accelerometer-based respiration sensor that replaces the pressure-sensing lead to enable synchronized upper-airway stimulation .
- In a 56-patient clinical trial for Inspire five, inspiratory cycle detection improved from 78% to 83%, meeting noninferiority requirements and indicating enhanced performance .
- A Singapore post-approval study reported a 20% reduction in implant time and an average of 6.0 hours of nightly therapy usage, underscoring procedural efficiency and patient adherence .
- The Inspire V system further offers multiple-electrode capability, an 11-year average battery life, and a flexible software platform for future remote programming and feature updates .
- Exhibit 99.1, presented at Wells Fargo 2025 MedTech Innovation Spotlight, is now available on the company’s IR website for investors .
- Comprehensive site training along with integration of the SleepSync programming system has been deployed to streamline physician adoption and device programming .
- Inspire V is now fully launched, offering a streamlined procedure that eliminates the pressure sensing lead and simplifies contract updates, positioning the company to more efficiently transition from Inspire IV amid patient warehousing concerns.
- Q1 performance was strong with 23% growth and the first positive earnings, setting a transitional framework for Q2 and anticipated higher utilization in Q3 and Q4.
- Future pipeline plans include enhancements like Inspire VI with auto-activation and SleepSync features, which aim to improve patient adherence and operational efficiency while expanding direct marketing efforts.
- Achieved $201.3M Q1 2025 revenue with 23% growth and turned around to a $3M net income (EPS of $0.10), reversing a previous loss
- Initiated the full U.S. launch of the Inspire V system, designed for reduced implant time and enhanced functionality
- Updated full-year guidance projects revenue between $940M-$955M, with an improved EPS outlook and gross margin guidance of 84%-86%
- Delivered robust clinical outcomes, achieving a median AHI reduction from 33.0 to 10.2 and improved therapy adherence compared to CPAP
- Additional context: Recorded $800M in 2024 revenue with 28% growth and treated over 100,000 patients
- Revenue guidance between $940M and $955M was reiterated with discussions on inventory management and timing of the Inspire V launch as key factors.
- The limited market release of Inspire V showed promising early results, highlighted by successful implants in Singapore and initial U.S. centers, with plans to present clinical data in June.
- The company is shifting its reporting metrics to focus on top-line revenue, earnings per share, and macro-level operational metrics such as territory managers and field clinical representatives, aiming to provide a clearer overview of performance.
- Updates include improved prior authorization processes and changes in reimbursement coding (reverting to the base code 64568) that are expected to streamline procedures and enhance operating efficiency.